Celltrion to Streamline Pharmacovigilance Reporting with Oracle Health Sciences Technology
Oracle, this week, announced that Celltrion (KOSDAQ: CELLTRION), a global leading biopharmaceutical company, has selected Oracle Health Sciences Argus and Oracle Health Sciences Empirica Signal to streamline its pharmacovigilance case management and patient safety initiatives – helping to bring more chronic disease and life-saving therapies to market more cost-effectively.
Driven by the cost saving potential of biosimilar drugs – an estimated $100 Billion in global healthcare spending cuts by the end of 2020* – there is an emergence of biosimilar drug manufacturers entering the market and regulatory bodies like the FDA are helping to accelerate getting these drugs to market. A key aspect in getting these treatments to market is safety and efficacy regulatory reporting, and Celltrion has turned to Oracle Health Sciences technology to help streamline the process.
“Since our founding in 2002, we have remained committed to making more advanced therapeutics available to everyone, and have turned to technology to help us achieve our goals. Oracle Health Sciences technology is supporting us in meeting today’s regulatory requirements and will enable us to move and shift as the regulatory landscape evolves, so that we can bring more life-saving and treatments to market safely and cost-effectively,” said Dr. Sang Joon Lee, vice president for Celltrion, Inc.
In an effort to streamline its pharmacovigilance case management and reduce IT costs, Celltrion has selected Oracle Health Sciences Argus Enterprise Edition which provides a comprehensive platform that will enable the company to make faster and better safety decisions, optimize global compliance and integrate risk management into key processes. Oracle Health Sciences Empirica Signal delivers a dynamic, visual data-mining environment that will enable Celltrion to detect safety signals, uncover patterns and recognize trends in spontaneous adverse event reporting.
“It is great to see the biopharmaceutical market headed in new and innovative directions as we are seeing with the emergence of more biosimilar manufacturers. Oracle Health Sciences remains committed to evolving and innovating to continue meeting the needs of our existing and potential customers,” said Steve Rosenberg, general manager, Oracle Health Sciences. “Celltrion is a glowing example of a biotech company that is innovating to help improve people’s lives.”
This article has been republished from materials provided by Oracle. Note: material may have been edited for length and content. For further information, please contact the cited source.
Compound Offers Pain-relief of Opioids Without Addictive PropertiesNews
Researchers have engineered a new compound that animal tests suggest could offer the pain-relieving properties of opioids such as morphine and oxycodone without the risk of addiction.READ MORE
E. Coli’s Internal Bomb Offers Chink In ArmourNews
Bacteria's internal bomb, the so-called toxin-antitoxin (TA) system that is part of the normal bacterial makeup, may be triggered to make bacteria turn on themselves, providing a valuable target for novel antimicrobial approaches in drug design.READ MORE